v3.26.1
Commitments and Contingencies - Securities Purchase and Licensing Agreement and April 2024 Agreement for Gelclair (Details)
3 Months Ended 6 Months Ended
Apr. 12, 2024
Mar. 18, 2024
USD ($)
$ / shares
shares
Jun. 30, 2026
USD ($)
Jun. 30, 2025
USD ($)
Jun. 30, 2026
USD ($)
Jun. 30, 2026
EUR (€)
Jun. 30, 2025
USD ($)
Dec. 31, 2025
USD ($)
Long-term Purchase Commitment                
Initial term of contract         5 years 5 years    
Non-refundable license fee         $ 215,040 € 200,000    
Deferred revenue     $ 468,000   468,000     $ 552,000
Royalty expense     142,000 $ 39,000 284,000   $ 78,000  
Amortization expense     467,000 467,000 934,000   934,000  
Insurance retention amount     100,000   100,000      
Accrual for loss contingency         0      
April 2024 Agreement for Gelclair                
Long-term Purchase Commitment                
Initial term of contract 5 years              
Royalty expense     142,000 39,000 284,000   78,000  
Amortization expense     6,000 $ 6,000 11,000   11,000  
Carrying amount of license     176,000   176,000     $ 187,000
Gen                
Long-term Purchase Commitment                
Issuance of common stock (in shares) | shares   13            
Purchase price of common stock (per shares) | $ / shares   $ 157,500            
Gross proceeds from the issuance of common stock   $ 2,000,000            
Deferred revenue recognized as revenue   $ 850,000            
Initial term of contract   5 years            
License granted         86,000   $ 86,000  
Deferred revenue     468,000   468,000      
Deferred revenue, current     170,000   170,000      
Deferred revenue, noncurrent     $ 298,000   $ 298,000